IL2 and autoimmune disease: Consistent with the findings, a prospective study performed by Rosenzwajg M. demonstrated the value of low-dose IL-2 in 11 autoimmune diseases, proposing that all patients had relatively specific amplification and activation of Tregs, and were well tolerated to low-dose IL-2 regardless of disease and concomitant therapy (24).